Subcutaneous bortezomib: In multiple myeloma

Drugs

Volumn 73, Issue 1, 2013, Pages 45-54

  Hoy, Sheridan M ^a  

^a Adis 41 ^*  (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; HYPERICUM PERFORATUM EXTRACT; KETOCONAZOLE; MELPHALAN; OMEPRAZOLE; ORAL ANTIDIABETIC AGENT; PREDNISONE; RITONAVIR;

ANEMIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ASTHENIA; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; DIARRHEA; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FATALITY; DRUG FORMULATION; DRUG INHIBITION; DRUG METABOLISM; DRUG POTENTIATION; DRUG TOLERABILITY; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; HIGH RISK PATIENT; HUMAN; INJECTION SITE PRURITUS; INJECTION SITE REACTION; LEUKOPENIA; MAXIMUM PLASMA CONCENTRATION; META ANALYSIS; METABOLISM; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEURALGIA; NEUTROPENIA; NEUTROPHIL COUNT; NUTRITION; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PROGRESSION FREE SURVIVAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; REVIEW; SENSORY NEUROPATHY; SIDE EFFECT; SKIN REDNESS; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT RESPONSE; WEIGHT REDUCTION;

ANTINEOPLASTIC AGENTS; BORONIC ACIDS; DISEASE-FREE SURVIVAL; HUMANS; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; MULTIPLE MYELOMA; PYRAZINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84877064781     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-013-0006-6     Document Type: Review

References (26)

1. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;364(11):1046-60.
2. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: multiple myeloma. 1.2013 [online]. http://www.nccn.org/ professionals/physician-gls/pdf/myeloma.pdf. Accessed 26 Nov 2012.
3. Mateos M-V. Subcutaneous bortezomib: a step towards optimised drug use. Lancet Oncol. 2011;12(5):410-1.
4. Curran MP, McKeage K. Bortezomib: a review of its use in patients with multiple myeloma. Drugs. 2009;69(7):859-88.
5. Janssen-Cilag International NV. Velcade 1 mg powder for solution for injection: summary of product characteristics. 2012. http://www.ema.europa.eu/ docs/en-GB/document-library/EPAR-Product-Information/human/000539/WC500048471. pdf. Accessed 2 Nov 2012.
6. ® (bortezomib) for injection: US prescribing information. 2012. http://www.accessdata.fda.gov/ drugsatfda-docs/label/2012/021602s027lbl.pdf. Accessed 14 Nov 2012.
7. Boccadoro M, Morgan G, Cavenagh J. Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy. Cancer Cell Int. 2005;5(1):18.
8. Hideshima T, Richardson PG, Anderson KC. Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma. Mol Cancer Ther. 2011;10(11):2034-42.
9. Moreau P, Richardson PG, Cavo M, et al. Proteasome inhibitors in multiple myeloma: 10 years later. Blood. 2012;120(5):947-59.
10. Wright JJ. Combination therapy of bortezomib with novel targeted agents: an emerging treatment strategy. Clin Cancer Res. 2010;16(16):4094-104.
11. Zangari M, Terpos E, Zhan F, et al. Impact of bortezomib on bone health in myeloma: a review of current evidence. Cancer Treat Rev. 2012;38(8):968-80.
12. Moreau P, Pylypenko H, Grosicki S, et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study.[published erratum appears in Lancet Oncol. 2011 Jun; 12(6):522]. Lancet Oncol. 2011;12(5):431-40.
13. Moreau P, Karamanesht II, Domnikova N, et al. Pharmacokinetic, pharmacodynamic and covariate analysis of subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma. Clin Pharmacokinet. 2012;51(12):823-9.
14. Arnulf B, Pylypenko H, Grosicki S, et al. Updated survival analysis of a randomized, phase 3 study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma. Haematologica. 2012;97(12):1925-8.
15. Millennium Pharmaceuticals Inc. A study of subcutaneous and intravenous Velcade in patients with previously treated multiple myeloma [ClinicalTrials.gov identifier NCT00722566]. US National Institutes of Health, ClinicalTrials.gov [online]. http://clinicaltrials.gov. Accessed 26 Nov 2012.
16. Bladé J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Br J Haematol. 1998;102(5):1115-23.
17. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003;348(26):2609-17.
18. Durie BG, Harousseau J-L, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20(9):1467-73.
19. Delforge M, Bladé J, Dimopoulos MA, et al. Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues. Lancet Oncol. 2010;11(11):1086-95.
20. Richardson PG, Sonneveld P, Schuster MW, et al. Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline. Br J Haematol. 2009;144(6):895-903.
21. Argyriou AA, Iconomou G, Kalofonos HP. Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature [published erratum appears in Blood. 2009;113(18):4478]. Blood. 2008;112(5):1593-9.
22. Palumbo A, Bringhen S, Rossi D, et al. Bortezomib-melphalan-prednisone- thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. J Clin Oncol. 2010;28(34):5101-9.
23. Mateos M-V, Oriol A, Martínez-López J, et al. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial. Lancet Oncol. 2010;11(10):934-41.
24. Ostendorf W. Administration of parenteral medication. In: Perry A, Potter P, Elkin MK, editors. Nursing interventions & clinical skills. 5th ed. St Louis: Elsevier Mosby; 2012. p. 541-83.
25. Fundamentals of administration. In: Polovitch M, Whitford J, Olsen M, editors. Chemotherapy and biotherapy guidelines and recommendations for practice. 3rd ed. Pittsburgh: Oncology Nursing Society; 2009. p. 73-104.
26. Berenson JR, Hillner BE, Kyle RA, et al. American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. J Clin Oncol. 2002;20(17):3719-36.